Terlipressin
From Wikipedia, the free encyclopedia
Terlipressin
|
|
Systematic (IUPAC) name | |
(2S)-1-[(4S,7S,10S,13S,16S,19S)-19-[[2- [[2-[(2-Aminoacetyl)amino]acetyl]amino] acetyl]amino]-13-benzyl-10-(2-carbamoylethyl)- 7-(carbamoylmethyl)-16-[(4-hydroxyphenyl) methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8, 11,14,17-pentazacycloicosane-4-carbonyl]-N- [(1S)-5-amino-1-(carbamoylmethylcarbamoyl) pentyl]pyrrolidine-2-carboxamide |
|
Identifiers | |
CAS number | |
ATC code | H01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C52H74N16O15S2 |
Mol. mass | 1227.37 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | ~30% |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | IV |
Terlipressin is an analogue of vasopressin used as a vasoactive drug in the management of hypotension. It has been found to be effective when norepinephrine does not help.
Indications for use include norepinephrine-resistant septic shock[1] and hepatorenal syndrome.[2] In addition, it is used in bleeding esophageal varices.[3]
Terlipressin is marketed under the brand name Glypressin (Ferring Pharmaceuticals).
[edit] See also
[edit] References
- ^ O'Brien A, Clapp L, Singer M (2002). "Terlipressin for norepinephrine-resistant septic shock". Lancet 359 (9313): 1209–10. doi: . PMID 11955542.
- ^ Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J (2000). "Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome". J Hepatol 33 (1): 43–8. doi: . PMID 10905585.
- ^ Ioannou G, Doust J, Rockey D. "Terlipressin for acute esophageal variceal hemorrhage". Cochrane Database Syst Rev: CD002147. doi: . PMID 12535432.
|